24 December 2024 : Original article
Lung Transplant Success in COVID-19 Patients Requiring V-V ECMO: One-Year Follow-Up
Mazen F. Odish


DOI: 10.12659/AOT.946088
Ann Transplant 2024; 29:e946088
Table 2 Peri-transplant characteristics and post-transplant events. Data are n (%), median (IQR), n, or n/n (%) unless stated otherwise.
Transplanted patients with COVID-19 ARDS | |
---|---|
Lung Allocation Score | 91.86 (89.0–92.1 |
Time on waitlist (days) | 21 (7–43) |
Type of transplant | |
Single | 0 (0%) |
Bilateral | 9 (100%) |
Surgery time (skin to skin) (min) | 485 (433–532) |
Ischemic time (min) | |
Right lung | 209 (181–229) |
Left lung | 279 (250–346) |
Intraoperative blood products (# units) | |
pRBC | 2 (1–6) |
FFP | 1 (0–2) |
Cryoprecipitate | 2 (0–2) |
Platelets | 0 (0–2) |
Induction therapy | |
Standard | 6 (66%) |
Non-standard | 2 (22%) |
Desensitization | 1 (11%) |
PGD at 72 hours | |
PGD 0 | 5 (56%) |
PGD 1 | 3 (33%) |
PGD 2 | 1 (11%) |
PGD 3 | 0 |
Length of mechanical ventilation after transplant (days) | 8 (6–15) |
Total length of ICU stay (days) | 76 (45–141) |
Length of hospital stay (days) | 89 (54–144) |
Need for supplemental oxygen at discharge | 0 (0%) |
Any ISHLT Grade rejection within 1 year | 3 (33%) |
Airway dehiscence within 30 days of transplant | 0 (0%) |
CLAD (1-year) | 2 (22%) |
Survival (1-year) | 9 (100%) |
pRBC – packed red blood cells; FFP – fresh frozen plasma; PGD – primary graft dysfunction; ICU – Intensive Care Unit; ISHLT – International Society for Heart and Lung Transplantation; CLAD – chronic lung allograft dysfunction. |